A review of current management of vasculo-Behcet's
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of review To give an overview of recently published articles about the management of vasculo-Behcet's with particular emphasis on anticoagulation. Recent findings Biologic agents are emerging as a potential therapeutic option in refractory vasculo-Behcet with a good safety profile. Evidence further shows that following nonpulmonary aneurysm repair, there is a reduced risk of recurrent aneurysmal formation at the operative site in patients treated with immunosuppressants in addition to their surgery, than those undergoing surgical intervention alone. Summary Behcet disease patients are at risk of developing multiple vascular complications including thrombosis and aneurysms. Treatment should focus on reducing inflammation; and the role of anticoagulation is still debatable. © Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved.
Description
Keywords
Anticoagulation, Behcet's disease, Thromboembolism, Treatment, Vascular disease, Adalimumab, Aneurysm, Anticoagulants, Antirheumatic agents, Azathioprine, Behcet syndrome, Cyclophosphamide, Cyclosporine, Etanercept, Glucocorticoids, Humans, Immunosuppressive agents, Infliximab, Interleukin 1 receptor antagonist protein, Rituximab, Thrombosis, Vascular surgical procedures, Alemtuzumab, Antithrombocytic agent, Biological product, Cyclosporin a, Glucocorticoid, Immunosuppressive agent, Monoclonal antibody, Anticoagulant agent, Antirheumatic agent, Interleukin 1 receptor blocking agent, Behcet disease, Clinical assessment, Clinical feature, Disease course, Endovascular surgery, Human, Managed care, Medline, Pathogenesis, Priority journal, Pulmonary artery aneurysm, Review, Systematic review, Vein thrombosis, Complication, Vascular surgery